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Abstract
Transabdominal ultrasound (US) is the first‐line imaging method used to diagnose
pancreatic lesions, but contrast techniques are needed to differentiate among inflam‐
matory and malignant lesions,  as  well  as  between pseudocysts  and cystic  tumors.
Contrast‐enhanced (CE) ultrasonography has been proven to be a useful tool in this
regard with performance similar to contrast‐enhanced computer tomography/magnetic
resonance  imaging (CT/MRI),  being also  safer  and nonirradiant.  According to  the
EFSUMB guidelines on the nonhepatic use of contrast‐enhanced ultrasound (CEUS),
this  method  is  useful  to  improve  characterization  of  ductal  adenocarcinoma;  to
differentiate between pseudocysts and cystic tumors; to differentiate vascular (solid)
from avascular (liquid/necrotic) components of a lesion; to better define the dimensions
and margins of a lesion, including its relationship with adjacent vessels; and to help the
choice for a next imaging technique.
Keywords: contrast‐enhanced ultrasound, pancreas, pancreatic adenocarcinoma, pan‐
creatic cystic lesions
1. Introduction
The pancreas, a retroperitoneal organ, is more difficult to evaluate by ultrasound (US), mostly
due to a poor acoustic window generated by the interposition of intestinal gas between the
transducer and the pancreas. In order to be able to correctly evaluate the pancreas, an experienced
operator is needed.
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On the other hand, US is a useful tool to identify pancreatic lesions, but ultrasound alone is
not enough for the differential diagnosis and staging of the identified lesions, especially if a
malignant tumor is suspected.
Contrast‐enhanced ultrasound (CEUS) is not useful for the detection of focal pancreatic lesions,
either solid or liquid. It is useful for the characterization of ultrasound‐detected lesions at this
level [1]. The technique can be used in acute and chronic pancreatitis (CP), in the characteri‐
zation of solid tumors: ductal adenocarcinoma or neuroendocrine tumors, in the characteri‐
zation of pseudocysts or pancreatic cystic tumors.
When a pancreatic tumor is detected, an immediate and correct differential diagnosis is
mandatory to establish the appropriate management [2]. Conventional ultrasound followed
by CEUS can provide a rapid assessment of the pancreatic lesion's pattern and can charac‐
terize the vascularization, thus making possible a differential diagnosis immediately after
detection.
CEUS has the advantage of being a real‐time imaging method that allows continuous visual‐
ization of vascular enhancement pattern, as opposed to contrast‐enhanced (CE) computer
tomography (CT) or magnetic resonance imaging (MRI), which only take snapshots at preset
time moments. Due to lack of side effects and irradiation, CEUS can be repeated immediately
if inconclusive.
The most frequently used ultrasound contrast agent for pancreas examination is SonoVue
(Bracco SpA, Milan, Italy), a second generation, strictly intravascular contrast agent, containing
sulfur hexafluoride–filled microbubbles encapsulated in a phospholipid shell. US contrast
agents have no influence on micro‐vascularity and can be also used in patients with renal
failure, and also allergic reactions are exceptionally rare [2, 3], as opposed to contrast‐enhanced
CT/MRI [4–7].
2. CEUS technique and CEUS aspect of the normal pancreas
For the CEUS examination of the pancreas, usually a 2.4 ml bolus of SonoVue is injected in an
antecubital vein, followed by a 10 ml bolus saline solution. Contrast‐specific US modes are
required for the contrast study. They are available on specific ultrasound systems and are
generally based on the cancellation and separation of linear US signals from the tissue and use
of the nonlinear response from the contrast agent microbubbles [1].
The examination is performed with low mechanical index, using conventional image for
orientation, and following in the same time the contrast study in a specific window. A “real‐
time” dynamic observation of the contrast‐enhanced phases – arterial (early stage of enhance‐
ment, until 30 s) and late (delayed stage of enhancement, 30–45 until 120 s following contrast
injection) – begins immediately after the contrast bolus [1]. The following aspects are followed
up during CEUS: timing and intensity of enhancement and the distribution of the contrast
agent.
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Approximately 25–40 s following the contrast bolus, the pancreas shows a homogeneous
intense enhancement due to its rich vascularity (Figure 1) [8]. Also due to the rich vascularity,
the pancreas has a rapid “wash‐out,” and 2 min following the contrast bolus, the pancreas
appears as hypoenhancing as compared to the nearby liver (Figure 2) [8]. Thus, CEUS is useful
especially for delineation of avascular pancreatic lesions.
Figure 1. CEUS of the normal pancreas, arterial phase: homogeneous intense enhancement (AO—aorta).
Figure 2. CEUS of the normal pancreas, late phase: the pancreas is hypoenhancing as compared to the liver (PV—por‐
tal vein; WD—Wirsung duct).
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3. Acute pancreatitis (AP)
AP is a potentially severe disease with unpredictable outcome which can develop multiple
complications with fast dynamics. The early differential diagnosis between a mild, edematous
form and a severe, necrotic‐hemorrhagic one is very important in order to be able to adapt the
treatment and to be able to try to prevent the occurrence of complications. Currently, contrast‐
enhanced CT (CE‐CT) is considered to be the reference method for the assessment and for
staging AP [9]. But CE‐CT is an irradiating, relatively expensive technique, and animal studies
have suggested a potential risk of aggravation of AP following CE‐CT due to pancreatic micro‐
circulation impairment by the contrast agent [10–12], even if in human studies this effect has
not been proven [13, 14]. Another impediment for CE‐CT is the need for repetitive examina‐
tions according to the patient's evolution. This is why a safer, cheaper diagnostic tool would
be useful for the diagnosis, staging, and follow‐up of patients with AP.
Abdominal US is in most cases the first imaging method used to evaluate patients with AP
since it is widely available, safe, rapid, and inexpensive. It is also nonirradiant, and thus, it can
be repeated as often as needed to follow‐up the patient's evolution. On the other hand, US has
limitations due to the poor acoustic window in AP secondary to large amount of bowel gas
and also due to the patient's abdominal pain which makes him unable to cooperate for an
optimal evaluation.
Standard abdominal US allows only assessment of the imaging aspect of the pancreas in AP,
without being able to assess vascularity. But it also reveals suggestive signs for a severe AP
such as hyperechoic bursa omentalis (Figure 3) and presence of intra‐peritoneal collections
(peripancreatic, pericolic or in the Douglas space), while using Doppler US, a splenic vein
thrombosis may be seen.
Figure 3. Acute pancreatitis, standard US: hypoechoic, inhomogeneous enlarged pancreas, hyperechoic bursa omenta‐
lis.
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CEUS allows visualization of pancreatic vascularity and thus is able to reveal necrotic areas
which will not enhance following the contrast bolus (Figure 4). But the same limitations as for
standard US apply for CEUS, which is useless if the acoustic window for the pancreas is poor.
Figure 4. Severe acute pancreatitis, CEUS, arterial phase: almost the entire pancreas is unenhancing, revealing exten‐
sive necrosis.
Rickes et al. evaluated the accuracy of CEUS for the diagnosis of AP severity, considering CE‐
CT as the reference method, and they found out that CEUS had 82% sensitivity (Se), 89%
specificity (Sp), 95% positive predictive value (PPV), and 67% negative predictive value (NPV)
for diagnosing severe AP, with a much lesser cost than CE‐CT [15]. Similar results were
obtained by other authors, CEUS Se and Sp ranging from 86 and 97%, respectively [16], to 90.3
and 98.8%, respectively (97.4% accuracy) [17].
Thus, all these studies confirmed the value of CEUS for detecting pancreatic necrosis and for
predicting the severity of AP. It showed similar results as compared with CE‐CT with fewer
side effects since CEUS is nonirradiant and since the US contrast agents have no influence on
microvascularity and can also be used in patients with renal failure.
4. Chronic pancreatitis (CP)
During the evolution of CP, inflammatory masses can appear, a characteristic feature of
pseudotumoral CP. Differential diagnosis between this entity and pancreatic cancer is often
difficult not only due to the similar imaging aspect but also due to similar clinical symptoms
[18]. The US aspect of pseudotumoral CP is most often of a hypoechoic, imprecisely delineated
mass in the head of the pancreas. CEUS is useful to differentiate among the two entities since
pancreatic adenocarcinomas are hypoenhancing following contrast (due to massive desmo‐
plastic reaction as well as poor vascularity), while the inflammatory pseudotumor in CP will
be enhancing in the arterial phase [19–21].
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D'Onofrio et al. evaluated the performance of CEUS to diagnose pseudotumoral CP in a study
that included 173 pancreatic masses. CEUS had 88.6% Se, 97.8% Sp, 91.2% PPV, and 96%
accuracy for the diagnosis of pseudotumoral CP, while in 94% of cases the inflammatory mass
showed moderate enhancement following contrast, similar to the adjacent pancreatic paren‐
chyma [20].
A more recent study showed that the blood flow ratio between the superior mesenteric artery
and the pancreatic parenchyma evaluated by CEUS correlates with the grade of chronic
pancreatitis and concluded that this safe and convenient method may be useful for the early
diagnose of CP [22].
A special entity is autoimmune pancreatitis. It is characterized by a high level of gamma‐
globulins or IgG, presence of auto‐antibodies, mild or absent clinical symptoms. Imaging
techniques reveal an enlarged, “sausage‐like” pancreas, with diffuse, irregular thinning of the
Wirsung duct (WD), with possible stenosis of the retro‐pancreatic main biliary duct and rarely
cysts or calcifications in the pancreatic parenchyma [20]. Autoimmune pancreatitis is some‐
times associated with other autoimmune diseases such as diabetes mellitus, inflammatory
bowel disease, primary biliary cirrhosis, primary sclerosing cholangitis, or lupus.
On standard US, in autoimmune pancreatitis the imaging changes are most often diffuse. The
pancreas is enlarged, hypoechoic and with a compressed Wirsung duct. Following contrast
bolus, the pancreas is moderate or hyperenhancing in the early arterial phase, but also with
inhomogeneous enhancement due to lymphocytic infiltration and fibrosis [20].
5. Solid focal pancreatic lesions
5.1. Ductal adenocarcinoma
Ductal adenocarcinomas represent 80–90% of the exocrine pancreatic tumors [23]. They have
a poor prognosis, due to both their aggressiveness and the difficult diagnosis in early phases,
in which effective treatment can be initiated.
On standard US, ductal adenocarcinoma most frequently appears as a hypoechoic, imprecisely
delineated mass which sometimes exceeds the contour of the pancreas (which facilitates
detection) (Figure 5), but which other times is completely embedded in the pancreatic
parenchyma.
In CEUS, ductal adenocarcinoma is only slightly enhancing in the early phase, appearing as
hypoenhancing as compared with the adjacent pancreatic parenchyma (Figure 6) probably
due to the desmoplastic reaction and low mean vascular density [20, 23–25]. This pattern is
present in approximately 90% of cases [2, 20, 26]. Moreover, CEUS enables a better visualization
and staging of ductal adenocarcinoma by allowing a better delineation as well as assessment
of vascular invasion [23, 27–29].
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Figure 5. Ductal adenocarcinoma in the head of the pancreas, standard US: hypoechoic mass (TU arrows). PA—
pancreas.
Figure 6. Ductal adenocarcinoma in the head of the pancreas, CEUS—arterial phase: hypoenhancing mass (TU—ar‐
rows) as compared to the adjacent pancreatic parenchyma (PA).
Also CEUS enables liver assessment in the late vascular phases, thus allowing visualization of
eventual metastases, with a better accuracy than standard US. In the late phase (more than
120 s after the contrast bolus), liver metastases will appear as hypoenhancing focal liver lesions.
5.2. Neuroendocrine tumors
Neuroendocrine tumors may be symptomatic if they are secreting, with specific clinical signs
according to the secreted hormone, or asymptomatic if they are nonfunctioning, in this case
only nonspecific symptoms are present, secondary to tumoral growth.
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Neuroendocrine tumors are hypervascular lesions [30]. On standard US, they have a similar
aspect to ductal adenocarcinoma, as hypoechoic masses (Figure 7). The differential diagnosis
among the two entities is extremely important, for prognosis, as well as for therapeutic strategy,
and this is where CEUS can make a difference.
Figure 7. Neuroendocrine tumor in the pancreatic head, standard US: hypoechoic mass (TU). Dilated main biliary duct
(MBD). GB—gallbladder.
On CEUS, there are different enhancing patterns according to the size and tumor vascularity
[23]. Thus, large tumors show an intense enhancement in the early phase, excepting the necrotic
areas that are unenhancing, while medium‐sized lesions will also by enhancing in the arterial
phase (Figure 8) [31]. Both types of lesions are hypoenhancing in the late phase (Figure 9). On
the other hand, nonfunctioning neuroendocrine tumors can be hypovascular due to their dense
hyaline stroma (they also appear as hypointense on CE‐CT) [31, 32].
Figure 8. Neuroendocrine tumor in the pancreatic head, CEUS—arterial phase: hyperenhancing mass (arrows). Dilated
main biliary duct (MBD). GB—gallbladder.
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Figure 9. Neuroendocrine tumor in the pancreatic head, CEUS—late phase: hypoenhancing mass (arrows). Dilated
main biliary duct (MBD). GB—gallbladder.
6. Cystic focal pancreatic lesions
6.1. Pseudocysts
Pseudocysts are the most frequent cystic pancreatic lesions and are characterized by a fibrous
wall with no epithelium [33]. On standard US, they usually appear as anechoic lesions in the
pancreatic area. Sometimes echoic material can be seen inside the lesions, usually in the lower
areas (Figure 10). Association with an episode of acute pancreatitis in the recent history of the
patient can be useful for a positive diagnosis.
Figure 10. Pancreatic cystic lesion, standard US. Anechoic well‐defined lesion, with thick, irregular walls that also have
echoic protrusions.
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In CEUS, pseudocysts appear as completely unenhancing due to the fact that they are avascular
structures, even if in standard US they may have an echoic content (Figure 11). This feature is
very important for the differential diagnosis with cystic pancreatic tumors [2, 23, 34]. The
method has up to 100% sensitivity and specificity in characterizing these lesions [34].
Figure 11. Pancreatic cystic lesion the same as in Figure 10, CEUS—arterial phase. Anechoic content with unenhancing
walls and protrusions. Definitive diagnosis: pancreatic pseudocyst.
6.2. Mucinous cystadenomas and cystadenocarcinomas
Mucinous cystadenomas of the pancreas are rather rare and considered to be premalignant
lesions. If found they should be resected to avoid malignant transformation. Differentiation
between pancreatic serous cystadenoma and mucinous cystadenoma is difficult and is based
on fine needle aspiration (FNA) that will reveal in the later high levels of carcinoembryonic
antigen (CEA) in the aspirated fluid as well as a low level of pancreatic enzymes [35, 36]. They
are cystic pancreatic masses, usually multilocular, rarely unilocular when they must be
differentiated from pancreatic pseudocysts and from serous cystadenomas [37–41].
On standard US, mucinous cystic tumors appear as cystic masses with thick wall and septa,
with echoic protrusions from the wall and with the content (mucin) not always anechoic,
sometimes with peripheric calcifications (Figure 12). On CEUS, the cystic wall as well as the
septa will enhance following the contrast bolus, being easy to differentiate from the unen‐
hancing content (Figure 13). The presence of enhancing walls, protrusions, and septa is the
differential element from pancreatic pseudocysts [23, 41–43].
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Figure 12. Large lesion in the body of the pancreas, standard US: lesion with thick walls and mixed content: anechoic
component as well as echoic protrusion.
Figure 13. Large lesion in the pancreatic body: CEUS—arterial phase: the walls and the protrusion are enhancing. Con‐
clusive for cystic tumor of the pancreatic body.
The diagnosis of intra‐ductal papillary mucinous neoplasms (IPMN), main‐duct or side
branch‐duct types, is based on MRI and endoscopic ultrasound. CEUS can be also helpful for
differentiating between perfused (tumoral) and nonperfused (clot) regions [44].
6.3. Serous cystadenomas
Serous cystadenomas are benign cystic lesions, with a lobulated microcystic structure with
thin and centrally oriented septa, which are vascularized on CEUS [43]. It may mimic a solid
lesion, both on conventional US and on CEUS, but they are hyperenhanced on CEUS [44].
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The criteria used for the differential diagnosis of pancreatic masses (standard US, Doppler US
and CEUS) are presented in Table 1.
Lesion Standard US Power Doppler US CEUS
Ductal
adenocarcinoma 
Hypoechoic
Imprecisely delineated
Dilated Wirsung duct
Vascular invasion
Metastases
Undetectable
tumoral 
vessels
Poorly vascularized tumor
(hypoenhancing)
Marginal tumoral vessels
Acute pancreatitis Hypoechoic
Imprecisely delineated
Necrotic areas
Thrombosis
Rarely detectable
vessels
Enhancement according to
necrosis and inflammation:
hyperenhancement in edematous
AP with unenhancement of the
necrotic areas
Chronic pancreatitis Dilated Wirsung duct
Calcifications
Rarely detectable
vessels
Enhancement according to
necrosis and inflammation:
Hypoenhancement in CP
Neuroendocrine tumors Hypoechoic
Well delineated
Undilated Wirsung duct
Rare vascular invasion
Metastases
Rarely detectable
tumor vessels
Hyperenhancing tumors
Cystadenomas Small cysts (<3 cm)
Small size calcifications
Fibrous septa
Undilated Wirsung duct
Undetectable tumor
vessels
Hyperenhancing tumors
Arteries accompanying the
fibrous septa
Cystadenocarcinomas Large size cysts (>5 cm)
Echoic areas inside the cyst
and septaUndilated Wirsung
duct Metastases
Rarely detectable
chaotic tumor
vessels
Enhancing echoic areas inside the
cyst
Pseudocysts Anechoic, well delineated lesion
Signs of acute/chronic pancreatitis
Signs of bleeding/calcifications
Accompanying changes of the
adjacent bowel
Rarely detectable
tumor vessels in
young lesions
Unenhancing walls
Table 1. Differential diagnosis of pancreatic masses [1, 9, 45, 46].
Several studies proved the utility of CEUS for the characterization of pancreatic tumors [2, 9,
17, 47–49]. The accuracy for the diagnosis of solid pancreatic lesions varies from 91.7% [2] to
92.9% [17] or 93.8% in other series [48].
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In a recent meta‐analysis that included 23 CEUS studies, the pooled estimate of CEUS
sensitivity for the diagnosis of ductal adenocarcinoma was 0.89 (95% CI, 0.85–0.92), while the
average specificity was 0.84 (95% CI, 0.77–0.89). For the differentiation of neoplastic and
nonneoplastic lesions, the reported pooled sensitivity and specificity were 0.95 (95% CI, 0.93–
0.96) and 0.72 (95% CI, 0.58–0.83) [50].
7. Contrast‐enhanced endoscopic ultrasound (CE‐EUS)
CE‐EUS combines the benefits of high‐resolution US to those of a contrast‐enhanced imaging
method. It has two subtypes with similar performance: contrast‐enhanced endoscopic Doppler
ultrasound (which uses a high mechanical index for examination and no special software) and
contrast‐enhanced low mechanical index endoscopic ultrasound (in which the examination is
made in contrast mode) [51]. CE‐EUS in Doppler mode is useful to differentiate between ductal
adenocarcinomas (in which only arterioles are seen] and pseudotumoral chronic pancreatitis
(in which both arterioles and venules can be identified by CE‐EUS Doppler) [52, 53].
CE‐EUS with low mechanical index has been used similarly to transabdominal CEUS to
differentiate between pseudotumoral CP and ductal adenocarcinoma, but also to guide FNA
in order to avoid avascular areas, improving the diagnostic accuracy of FNA [54]. Quantitative
postprocedural assessment of uptake of the contrast agent has been proven useful to improve
the accuracy of CE‐EUS with low mechanical index for differentiating between the two
entities [55, 56].
As a conclusion, we must cite the EFSUMB guidelines on the nonhepatic use of CEUS, which
state that CEUS is useful to improve characterization of ductal adenocarcinoma (A;1b); to
differentiate between pseudocysts and cystic tumors (A;1b); to differentiate vascular (solid)
from avascular (liquid/necrotic) components of a lesion (A;1b); to better define the dimensions
and margins of a lesion, including its relationship with adjacent vessels (B;2b); to help the
choice for a next imaging technique (C;5) [1].
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